Another recent trial of CD19 CAR T cell therapy in combination with PD-1 blockade in 14 children with heavily pre-treated B-ALL provided further evidence of the safety profile of this combination therapy. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.